TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A report from Democrats on the Joint Economic Committee says President Donald Trump’s pharmaceutical stock holdings rose from a reported maximum of $1.7 million in 2024 to as much as $56.2 million at the end of 2025. It says up to $39.1 million was invested in companies benefiting from exemptions to Medicare drug-price negotiations. The White House says Trump’s portfolio is independently managed and denies a conflict of interest.
A report released by the Democratic minority arm of the Joint Economic Committee says President Donald Trump’s reported pharmaceutical stock holdings rose to as much as $56.2 million at the end of 2025, including up to $39.1 million in companies that benefited from exemptions to Medicare drug-price negotiations. The report raises questions about potential conflicts as Trump promotes lower prescription costs, while the White House says his portfolio is independently managed and denies any conflict of interest.
The report compared a maximum reported value of $1.7 million in pharmaceutical holdings in 2024 with a maximum of $56.2 million at the end of 2025. Its authors said as much as $39.1 million of the latter amount was in companies that benefited from a provision in the Republican-backed 2025 tax and spending law. That provision expanded an exemption affecting which medicines can be subject to Medicare price negotiations.
Committee Democrats’ analysis of Trump’s financial disclosures also identified up to $2.55 million in purchases of shares in companies benefiting from the exemptions on three dates before Trump signed the legislation in July 2025. It counted up to $950,000 in purchases on July 1, the day the Senate passed the bill. In August, after the bill became law, the portfolio bought as much as $1 million in AbbVie stock, the analysis said.
The report says Trump’s portfolio continued trading pharmaceutical shares during the first eight months of 2026, adding as much as $3.5 million in stock wealth in the sector. Those figures are based on financial disclosures and ranges of reported values; the report does not establish that Trump personally selected or directed the trades. A White House spokesperson said third-party financial institutions manage the portfolio.
Holdings and Medicare Drug Costs
The findings matter because the companies’ products and the Medicare exemption are tied to a policy with potential effects on prescription costs for older adults and other beneficiaries. The report estimates that Medicare beneficiaries taking pembrolizumab, sold as Keytruda by Merck, or nivolumab, sold as Opdivo by Bristol Myers Squibb, could pay roughly $5,000 more per year than if Medicare negotiated prices for those medicines. That is the report’s estimate, not a confirmed bill increase for every patient.
The report also puts the president’s investments alongside his administration’s public emphasis on lowering drug prices. The overlap may prompt scrutiny of how financial interests are managed when federal policy affects companies in which a president holds investments. The disclosed figures do not, by themselves, show that Trump influenced the law or investment decisions. The White House disputes that a conflict exists and says he has no ability to direct the portfolio.
medicare drug price negotiation tools
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Medicare Exemption Expanded
A law enacted under President Joe Biden established Medicare’s ability to negotiate prices for some of the costliest prescription drugs. The 2025 Republican tax and spending law expanded an existing exemption for medicines developed to treat rare diseases or conditions. According to health policy research nonprofit KFF, the change can delay when certain drugs become eligible for negotiations or exclude them from the program.
The carveout is often called the orphan drug exclusion. Supporters of expanding it argued that the exemption could encourage companies to develop treatments for rare diseases. Critics argue that some high-revenue medicines can benefit from the policy and remain outside negotiations that might lower costs for Medicare and its beneficiaries. The Democratic report identifies pharmaceutical firms whose products it says benefited from the change; the existence of a holding in a company does not itself establish the president’s role in shaping the policy.
“Outrageous and yet typical from this president, who makes the American people foot the bill again and again for his own gains.”
— Sen. Maggie Hassan, a Democrat who leads the Joint Economic Committee’s minority arm
As an affiliate, we earn on qualifying purchases.
What the Disclosures Do Not Establish
The report describes holdings and purchases using maximum values drawn from financial disclosures. It does not show that Trump personally chose each stock, directed the timing of purchases, or took part in decisions about the Medicare exemption because of his investments. The White House says third parties manage the portfolio, but the supplied report does not provide further detail about the institutions’ instructions, safeguards, or communications with the president.
It is also not clear from the report how the value of the holdings changed after the end of 2025, beyond its statement that pharmaceutical trading continued through the first eight months of 2026. The estimate of roughly $5,000 in additional annual costs for some patients depends on the report’s comparison with hypothetical negotiated prices; it is not presented as a final amount paid by every beneficiary. The available information does not resolve how many patients would be affected or the precise effects of the exemption for each medicine.
pharmaceutical investment analysis books
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Disclosures and Policy Review
The report’s release is likely to keep attention on Trump’s financial disclosures, the management of his portfolio, and the effects of the 2025 law’s Medicare provisions. The supplied material does not identify a formal investigation or a scheduled congressional hearing tied to the report, so no specific official next step is confirmed.
Further disclosures could clarify the portfolio’s holdings and transactions after August 2026, while additional policy analysis may refine which medicines qualify for the expanded exemption and how that affects Medicare prices. For now, the central dispute remains whether the disclosed investments create an appearance of a conflict and how much the exemption changes costs for beneficiaries; the administration denies a conflict, and the report’s estimates are not a final accounting of individual patients’ expenses.
medicare prescription assistance programs
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the Democratic report find about Trump’s pharmaceutical holdings?
It said the holdings rose from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025. The report attributed up to $39.1 million of the 2025 amount to companies benefiting from Medicare negotiation exemptions.
Did the report show that Trump personally directed the stock purchases?
No. The report analyzes financial disclosures and reported purchase ranges; it does not establish that Trump personally chose or directed the trades. The White House says third-party financial institutions independently manage the portfolio.
What is the Medicare drug-price exemption at issue?
The 2025 tax and spending law expanded an existing exemption for certain medicines developed to treat rare diseases or conditions. KFF says the change can delay some drugs’ eligibility for Medicare negotiations or exclude them from the program.
Could patients pay more for medicines covered by the exemption?
The report estimated that beneficiaries receiving Keytruda or Opdivo could pay roughly $5,000 more annually than they would if Medicare negotiated prices for those drugs. That is an estimate in the report, not a confirmed increase for every patient.
Has the White House responded to the allegations?
Yes. Spokesperson Davis Ingle said the portfolio is independently managed by third-party financial institutions and that Trump and his family cannot direct or influence its investments. He denied that the portfolio creates a conflict of interest.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
